PHARMACY

Actavis, QRxPharma partner to sell MoxDuo IR

BY Alaric DeArment

MORRISTOWN, N.J. — Drug maker Actavis is partnering with QRxPharma to sell what the former called a novel pain drug in the United States.

The company said Wednesday that the two had signed a letter of intent to commercialize MoxDuo IR (morphine and oxycodone), which they plan to launch in third quarter 2012.

"This partnership represents a major step in our strategy to further strengthen our position as on eof the major players in the segment of pain management in the U.S.," Actavis CEO Claudio Albrecht said. "Furthermore, as this latest development highlights, Actavis is serious in its quest to be ahead of the changing generic pharmaceutical industry. In the future, there will not be such a clear difference between innovator and generic companies. The lines between the two models are blurring. The generics business as we know it today will be gone within the next 10 years."


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

WAG study: Patient adherence with 90-day Rx at retail as good or better than mail order

BY Michael Johnsen

DEERFIELD, Ill. — Medication adherence is as high or slightly better among patients filling 90-day prescriptions at retail versus mail order, according to a new Walgreens study published in the November issue of the American Journal of Managed Care that the chain highlighted Thursday.

According to the study, adherence levels for 90-day at retail were 77%, while at mail-order adherence levels were 76%.

"Patients who fill maintenance prescriptions at retail have a statistically significantly higher [medication possession ratio] than patients who fill their prescriptions via mail," wrote Nikhil Khandelwal, lead author of the study and Walgreens manager of pharmacoeconomics and outcomes research. MPR represents the percentage of time a patient has access to medication. "The retail setting may present advantages related to quality of care and patient convenience. However, additional studies are needed to better understand factors which may contribute to this result."

“We know that improving patient adherence is critical,” said Jeffrey Kang, Walgreens SVP pharmacy, health and wellness services and solutions. “Given that community pharmacy also provides patients the potential benefit of face-to-face interaction with a pharmacist to help them manage their medications and overall wellness, these findings suggest that a 90-day at retail option in health plans potentially drives better patient outcomes and reduced costs for employers and payers.”

For the study, de-identified pharmacy claims data from a large pharmacy benefit manager were analyzed. Patients were selected if they were continuously eligible for at least 12 months between January 2008 and August 2010, with plan designs that allowed the option of filling 90-day supplies at either retail or mail order. Adherence was measured by medication possessions ratio for nine therapeutic groups (antiasthmatics and bronchodilators, antidepressants, antidiabetics, antihyperlipidemics, antihypertensives, beta blockers, calcium channel blockers, diuretics and thyroid agents).

The full study is available online.


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

American Diabetes Association CEO to serve as National Health Council board chairman

BY Allison Cerra

WASHINGTON — Larry Hausner, the CEO of the American Diabetes Association, will serve as the 2012 chairman of the National Health Council’s board of directors, NHC said.

Hauser, who has served as ADA CEO since 2007, brings more than 20 years of extensive management experience in nonprofits, coupled with a strong understanding of mission-driven organizations, to his role, the organization said. In the coming year, NHC — which brings together segments of the health community to provide a united voice for the more than 133 million people with chronic diseases and disabilities and their family caregivers — will focus on the following issues:

  • Working with various federal agencies to define essential health benefits, required under the healthcare-reform law, in a way to balance effective coverage with appropriate cost;

  • Encouraging the development of new treatments and diagnostic tools for people with chronic conditions through passage of HR 3497, the MODDERN Cures Act;

  • Encouraging sustained funding for federal health programs and health research; and

  • Supporting comparative effectiveness research and the work of the Patient-Centered Outcomes Research Institute (PCORI).

NHC consists of 100 national health-related organizations and businesses, including approximately 50 of the nation’s leading patient advocacy groups, which control its governance. Other members include professional and membership associations, nonprofit organizations with an interest in health, and major pharmaceutical, medical device, health insurance and biotechnology companies.


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES